According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
Several other research firms have also weighed in on RARX. Jefferies Group LLC reiterated an in-line rating and set a $25.00 price objective on shares of Ra Pharmaceuticals in a research note on Tuesday, March 7th. BMO Capital Markets increased their price objective on shares of Ra Pharmaceuticals from $24.00 to $31.00 and gave the stock a positive rating in a research note on Tuesday, March 7th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $26.75.
Ra Pharmaceuticals (NASDAQ:RARX) traded down 0.87% during trading on Tuesday, reaching $22.87. The company had a trading volume of 6,914 shares. The firm’s market capitalization is $515.63 million. The company’s 50-day moving average is $21.65 and its 200 day moving average is $17.32. Ra Pharmaceuticals has a 52 week low of $12.05 and a 52 week high of $24.12.
COPYRIGHT VIOLATION WARNING: This article was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2017/04/21/ra-pharmaceuticals-inc-rarx-raised-to-hold-at-zacks-investment-research-updated.html.
Several large investors have recently made changes to their positions in RARX. Teachers Advisors LLC purchased a new stake in shares of Ra Pharmaceuticals during the fourth quarter valued at approximately $135,000. Fred Alger Management Inc. purchased a new stake in shares of Ra Pharmaceuticals during the fourth quarter valued at approximately $223,000. Norges Bank purchased a new stake in shares of Ra Pharmaceuticals during the fourth quarter valued at approximately $304,000. State Street Corp purchased a new stake in shares of Ra Pharmaceuticals during the fourth quarter valued at approximately $1,060,000. Finally, FIL Ltd purchased a new stake in shares of Ra Pharmaceuticals during the fourth quarter valued at approximately $1,975,000. Institutional investors own 2.55% of the company’s stock.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.